E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Phospholipases and Lipases: Targets for Drug Development"

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 28 February 2018

Special Issue Editor

Guest Editor
Prof. Dr. Dimitra Hadjipavlou-Litina

Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, Greece
Website | E-Mail
Phone: +302310997627
Interests: design; synthesis; bilogical evaluation; inflammation; cancer; cardiovascular diseases; COX and LOX inhibitors; QSAR

Special Issue Information

Dear Colleagues,

Lipases and phospholipases govern mammalian metabolism. They share many common features; however, they differ from other metabolic enzymes. Their potential as drug targets for the treatment of metabolic diseases, cancer, atheromatosis, neurogenerative diseases and inflammation is widely recognized, and the first lipase inhibitor drugs have been successfully introduced.

The potential for phospholipases as targets for treating atherogenesis has become more prominent over the past year with the publication of the results of Phase 2 clinical trials of two inhibitors of forms of phospholipase A2: darapladib (GSK), which inhibits lipoprotein-associated phospholipase A2 and varespladib (Anthera) an inhibitor of several secreted phospholipase A2s.

Phospholipase A2 is a known mediator of inflammation, atherosclerosis and cancer in mammals. Inhibition of PLA2 alters cancer. It, therefore, makes the enzyme a potential drug target. Furthermore, phospholipases can be used for liposome-based drug delivery and as diagnostic tools.

Prof. Dr. Dimitra Hadjipavlou-Litina
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • phospholipase inhibitors
  • lipase inhibitors
  • drug targets
  • cytosolic
  • secreted phospholipase
  • serine lipase
  • atheromatosis
  • neurogeneration
  • obesity
  • metabolism

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Research

Open AccessArticle Evaluation of Rhamnetin as an Inhibitor of the Pharmacological Effect of Secretory Phospholipase A2
Molecules 2017, 22(9), 1441; doi:10.3390/molecules22091441
Received: 25 July 2017 / Revised: 28 August 2017 / Accepted: 29 August 2017 / Published: 31 August 2017
PDF Full-text (1174 KB) | HTML Full-text | XML Full-text
Abstract
Rhamnetin (Rhm), 3-O-methylquercetin (3MQ), and Rhamnazin (Rhz) are methylated derivatives of quercetin commonly found in fruits and vegetables that possess antioxidant and anti-inflammatory properties. Phospholipase A2 (PLA2) displays several important roles during acute inflammation; therefore, this study aimed at investigating new
[...] Read more.
Rhamnetin (Rhm), 3-O-methylquercetin (3MQ), and Rhamnazin (Rhz) are methylated derivatives of quercetin commonly found in fruits and vegetables that possess antioxidant and anti-inflammatory properties. Phospholipase A2 (PLA2) displays several important roles during acute inflammation; therefore, this study aimed at investigating new compounds able to inhibit this enzyme, besides evaluating creatine kinase (CK) levels and citotoxicity. Methylated quercetins were compared with quercetin (Q) and were incubated with secretory PLA2 (sPLA2) from Bothrops jararacussu to determine their inhibitory activity. Cytotoxic studies were performed by using the J774 cell lineage incubated with quercertins. In vivo tests were performed with Swiss female mice to evaluate decreasing paw edema potential and compounds’ CK levels. Structural modifications on sPLA2 were made with circular dichroism (CD). Despite Q and Rhz showing greater enzymatic inhibitory potential, high CK was observed. Rhm exhibited sPLA2 inhibitory potential, no toxicity and, remarkably, it decreased CK levels. The presence of 3OH on the C-ring of Rhm may contribute to both its anti-inflammatory and enzymatic inhibition of sPLA2, and the methylation of ring A may provide the increase in cell viability and low CK level induced by sPLA2. These results showed that Rhm can be a candidate as a natural compound for the development of new anti-inflammatory drugs. Full article
(This article belongs to the Special Issue Phospholipases and Lipases: Targets for Drug Development)
Figures

Back to Top